Published

Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Hearing research
Date: 2026-08-01
Source: PubMed
DOI: 10.1016/j.heares.2026.109701
PubMed: 42289149

Authors

Lu S Zhang Z Xue X Jiang Y Zhang C Liu P He D Shen W Yang S Wang F

Watch author

Derived topics and classifications

psilocybin Depression Anxiety End-of-Life Distress Neuroplasticity Mechanism of Action Receptor Pharmacology Aging Clinical Trial Review Article Adverse Events Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus.2026-08-01

Related papers

Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01 Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric DisordersPsychiatry and Clinical Psychopharmacology · 2026-03-30 Editorial: Psychedelic substances and neurological diseases: from basics to clinical applicationFrontiers in Pharmacology · 2026-03-15 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanismsNeuropharmacology · 2026-05-01 Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action.Pharmacology research & perspectives · 2026-04-01 A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populationsTherapeutic Advances in Psychopharmacology · 2026-02-28 A novel psychedelic 5-HT receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer.Journal of psychopharmacology (Oxford, England) · 2026-01-01